.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Robert E. Schoen, MD, MPH

Articles

ctDNA as a Marker of Recurrence Risk in stage III CRC: The α-CORRECT Study

March 13th 2025

Dr. Robert E. Schoen presents findings from the α-CORRECT study, highlighting the potential of circulating tumor DNA (ctDNA) as a biomarker for recurrence risk assessment in patients with stage III colorectal cancer.